Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

UOCT vs UNOV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

UNOV Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 3–0 Matrix Metrics)

UNOV Overall Winner 6-Pillar Tally: UOCT 0 – 0 UNOV (6 Tie) Matrix Metrics: UOCT 0 – 3 UNOV

As of Nov 16, 2026, Innovator U.S. Equity Ultra Buffer ETF - November (UNOV) is the stronger overall head-to-head candidate over Innovator U.S. Equity Ultra Buffer ETF - October (UOCT) in the Tradestie Institutional Equity Comparison Engine, winning 3–0 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). UOCT carries a Unified Composite Score of 57.2/100 (HOLD) at $41.76 (N/M Forward P/E, N/A operating margin), whereas UNOV carries 58.7/100 (HOLD) at $41.13 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: UOCT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.3); meanwhile UNOV trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About UOCT vs UNOV
UOCT Cboe BZX
Innovator U.S. Equity Ultra Buffer ETF - October
Institutional Equity
$41.76
-1.09% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.42β · 12% Vol
Unified Composite Score
57.2 / 100 HOLD
Tech 48.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope 0.4%) with fading momentum, RSI 40
RSI-14: 40.3 · SMA20: $42.32 · SMA50: $42.39
UNOV Cboe BZX Head-to-Head Winner
Innovator U.S. Equity Ultra Buffer ETF - November
Pharmaceutical Preparations
$41.13
-0.95% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.46β · 11% Vol
Unified Composite Score
58.7 / 100 HOLD
Tech 48.0 Fund 60.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.3 · SMA20: $41.59 · SMA50: $41.48

6-Pillar Scorecard Institutional Category Breakdown (UOCT 0 – 0 UNOV)

Columns: Metric · UOCT · UNOV
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Pharmaceutical Preparations Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: UOCT (0) vs UNOV (3)
Institutional Metric UOCT UNOV Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
77% ($38–$43) 84% ($37–$42) Stronger Trend UNOV
Beta / 30D Volatility
Risk Regime
0.42β · 12% Vol 0.46β · 11% Vol Lower Realized Risk UNOV
Unified Institutional Score
Composite Signal
57.2 / 100 (HOLD) 58.7 / 100 (HOLD) Higher Composite UNOV
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon UNOV +0.79 pp
UOCT: -1.76% · UNOV: -0.97%
3M Horizon UNOV +0.73 pp
UOCT: -0.29% · UNOV: +0.44%
6M Horizon UNOV +0.65 pp
UOCT: +2.77% · UNOV: +3.42%
1Y Horizon UNOV +0.89 pp
UOCT: +8.64% · UNOV: +9.53%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UOCT vs UNOV. Trailing 12-month operating profitability (UOCT N/A vs UNOV N/A) and valuation multiples (UOCT N/M vs UNOV N/M Forward P/E) are benchmarked directly in Pillar 4 below.

UOCT ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
UNOV ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
UOCT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UOCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
UNOV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UNOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
UOCT Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
UNOV Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ UOCT vs UNOV Key Questions & Quantitative Answers

As of Nov 16, 2026, Innovator U.S. Equity Ultra Buffer ETF - November (UNOV) is the stronger overall head-to-head candidate over Innovator U.S. Equity Ultra Buffer ETF - October (UOCT) in the Tradestie Institutional Equity Comparison Engine, winning 3–0 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). UOCT carries a Unified Composite Score of 57.2/100 (HOLD) at $41.76 (N/M Forward P/E, N/A operating margin), whereas UNOV carries 58.7/100 (HOLD) at $41.13 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: UOCT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 40.3); meanwhile UNOV trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

UOCT and UNOV split Growth & Scale metrics: UOCT posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with UNOV at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, UOCT generates N/A in USD-normalized revenue versus N/A for UNOV. In operating R&D and SG&A reinvestment, UOCT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for UNOV.

UOCT and UNOV trade at balanced relative valuation multiples. UOCT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas UNOV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UOCT (N/A ROE) versus UNOV (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, UOCT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.42β · 12% Vol realized risk). By comparison, UNOV carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.46β · 11% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Innovator U.S. Equity Ultra Buffer ETF - October (UOCT) Research Suite

Innovator U.S. Equity Ultra Buffer ETF - November (UNOV) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.